No. 24-428

Edwards Lifesciences Corporation, et al. v. Meril Life Sciences Pvt. Ltd., et al.

Lower Court: Federal Circuit
Docketed: 2024-10-16
Status: Denied
Type: Paid
Amici (1)Response RequestedResponse WaivedRelisted (2) Experienced Counsel
Tags: federal-circuit hatch-waxman-act patent-infringement regulatory-use safe-harbor statutory-interpretation
Key Terms:
Patent
Latest Conference: 2025-01-10 (distributed 2 times)
Question Presented (AI Summary)

Whether, under Hatch-Waxman's safe harbor, an infringing act is 'solely for uses reasonably related' to the federal regulatory process, when the infringing act is performed for both regulatory and nonregulatory uses

Question Presented (OCR Extract)

QUESTION PRESENTED This case presents an exceptionally important question regarding the proper scope of the Hatch-Waxman Act’s regulatory safe harbor. Under the Act, Congress declared that “[i]t shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention * * * solely for uses reasonably related” to the federal regulatory process. 35 U.S.C. 271(e)(1) (emphasis added). In a split decision, the Federal Circuit held that Section 271(e)(1)’s safe harbor applies by identifying any regulatory “use,” even if there are “additional” non-regulatory uses (including blatant commercial conduct) by the infringing party. The dissent disagreed: an infringing act with “alternative uses” is not “solely for [regulatory] uses” (35 U.S.C. 271(e)(1))—and the circuit’s contrary position “ignore[s]” the “word ‘solely’ in the statute,” invites “future mischief,” and cements an “unsupported expansion of the safe harbor.” This issue is significant. It frequently arises in disputes with massive stakes. It is the repeat subject of industry and expert analysis. It has split Federal Circuit panels, divided district courts, and prompted criticism from judges and academics. This Court has twice granted review to consider the scope of the same safe-harbor its obvious importance. And it sets the proper boundary between innovation and competition in a trillion-dollar industry. The question presented is: Whether, under Hatch-Waxman’s safe harbor, an infringing act is “solely for uses reasonably related” to the federal regulatory process, when the infringing act is performed for both regulatory and non-regulatory uses. (I)

Docket Entries

2025-01-13
Petition DENIED.
2024-12-27
Reply of Edwards Lifesciences Corporation, et al. submitted.
2024-12-27
Reply of petitioners Edwards Lifesciences Corporation, et al. filed. (Distributed)
2024-12-24
DISTRIBUTED for Conference of 1/10/2025.
2024-12-20
Brief of Meril Life Sciences Pvt. Ltd., et al. in opposition submitted.
2024-12-20
Brief of respondents Meril Life Sciences Pvt. Ltd., et al. in opposition filed. (Distributed)
2024-11-25
Waiver of the 14-day waiting period for the distribution of the petition pursuant to Rule 15.5 filed by petitioners.
2024-11-20
Response Requested. (Due December 20, 2024)
2024-11-19
DISTRIBUTED for Conference of 12/6/2024.
2024-11-15
Waiver of right of respondent Meril Life Sciences Pvt. Ltd., et al. to respond filed.
2024-11-15
Brief amicus curiae of Advanced Medical Technology Association filed. (Distributed)
2024-10-11
Petition for a writ of certiorari filed. (Response due November 15, 2024)

Attorneys

Advanced Medical Technology Association
Daniel N. LermanKramer Levin Naftalis & Frankel LLP, Amicus
Daniel N. LermanKramer Levin Naftalis & Frankel LLP, Amicus
Edwards Lifesciences Corporation, et al.
Daniel L. GeyserHaynes and Boone, LLP, Petitioner
Daniel L. GeyserHaynes and Boone, LLP, Petitioner
Meril Life Sciences Pvt. Ltd., et al.
J. David HaddenFenwick & West LLP, Respondent
J. David HaddenFenwick & West LLP, Respondent